Evidence map›Paper›PMID 33346877›Full record

ArticleJournal of cancer research and clinical oncology2021

Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

Thomas Wiegel, Peter Albers, Detlef Bartkowiak, Roswitha Bussar-Maatz, Martin Härter, Glen Kristiansen, Peter Martus, Stefan Wellek, Heinz Schmidberger, Klaus Grozinger and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Thomas WiegelDepartment of Radiotherapy and Radiation Oncology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. thomas.wiegel@uniklinik-ulm.de.ORCID http://orcid.org/0000-0003-1363-1410
Peter AlbersDepartment of Urology, University Hospital Düsseldorf, Düsseldorf, Germany.
Detlef BartkowiakDepartment of Radiotherapy and Radiation Oncology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Roswitha Bussar-MaatzPREFERE Project Management, German Cancer Society, Berlin, Germany.
Martin HärterDepartment of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Glen KristiansenInstitute of Pathology, University Hospital Bonn, Bonn, Germany.
Peter MartusDepartment of Clinical Epidemiology and Applied Biostatistics, University Hospital Tübingen, Tübingen, Germany.
Stefan WellekDepartment of Medical Biostatistics, Epidemiology and Informatics, University of Mainz, Mainz, Germany.
Heinz SchmidbergerDepartment of Radiotherapy and Radiation Oncology, University Hospital Mainz, Mainz, Germany.
Klaus GrozingerDepartment of Urology, Klinikum Leverkusen, Leverkusen, Germany.
Peter RennerCenter for Urology, Lübeck, Germany.
Fried SchneiderDepartment of Urology, Klinikum Lippe Detmold, Detmold, Germany.
Martin BurmesterDepartment of Urology, Vinzenzkrankenhaus, Hannover, Germany.
Michael StöckleDepartment of Urology, University Hospital Homburg/Saar, Homburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33346877
PMCPMC7919773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.